10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTER ENDED JUNE 30, 2008

0-28092
(Commission file number)

Medical Information Technology, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Massachusetts
(State of Incorporation)

04-2455639
(IRS Employer Identification Number)

Meditech Circle, Westwood, MA
(Address of Principal Executive Offices)

02090
(Zip Code)

781-821-3000
(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

There were 35,687,426 shares of Common Stock, $1.00 par value, outstanding at June 30, 2008.

Page 1 of 11

Index to Form 10-Q	Page
Part I - Financial Information
Item 1 - Consolidated Financial Statements (Unaudited)
Consolidated Balance Sheet as of December 31, 2007 and June 30, 2008	3
Consolidated Income Statement for the Three and Six Months Ended
June 30, 2007 and 2008	4
Consolidated Cash Flow Statement for the Six Months Ended
June 30, 2007 and 2008	5
Notes To Consolidated Financial Statements	6
Item 2 - Management's Discussion and Analysis of Financial Condition and
Results of Operations	8
Item 3 - Quantitative and Qualitative Disclosures About Market Risk	10
Item 4 - Controls and Procedures	10
Part II - Other Information
Item 1 - Legal Proceedings	10
&nb sp;Item 1A - Risk Factors	10
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3 - Defaults Upon Senior Securities	11
Item 4 - Submission of Matters to a Vote of Shareholders	11
Item 5 - Other Information	11
Item 6 - Exhibits	11
Signatures	11

Page 2 of 11

Part I - Financial Information

Item 1 - Consolidated Financial Statements (Unaudited)

Consolidated Balance Sheet as of December 31, 2007 and June 30, 2008

	Dec 31, 2007	Jun 30, 2008
Cash and equivalents	$22,567,940	$19,205,366
Marketable securities	210,137,628	182,831,468
Accounts receivable, less reserve	37,445,841	43,248,732
Current assets	270,151,409	245,285,566
Computer equipment	9,361,351	9,029,771
Furniture and fixtures	38,752,354	40,724,770
Building s	175,130,131	179,274,817
Land	33,159,107	33,159,107
Accumulated depreciation	(87,690,598)	(89,295,165)
Fixed assets	168,712,345	172,893,300
Marketable securities	30,000,000	30,000,000
Other assets	13,625,289	13,078,305
Total assets	$482,489,043	$461,257,171
Accounts payable	$395,117	$4,347,052
Taxes payable	5,377,659	2,129,068
Accrued expenses	34,475,953	23,434,802
Customer deposits	25,604,508	25,827,098
Deferred taxes and tax reserves	3,171,231	(4,130,863)
Total liabilities	69,024,468	51,607,157
Common stock, $1.00 par value,
authorized 40,000,000 shares,
issued& nbsp;and outstanding 35,481,271
in 2007 and 35,687,426 in 2008	35,481,271	35,687,426
Additional paid-in capital	54,869,077	62,290,657
Retained income	321,703,233	314,664,895
Unrealized security gains (losses), net of tax	1,410,994	(2,992,964)
Shareholder equity	413,464,575	409,650,014
Total liabilities and shareholder equity	$482,489,043	$461,257,1 71

Page 3 of 11

Consolidated Income Statement for the Three and Six Months Ended June 30, 2007 and 2008

	3 months	ended on	6 months	ended on
	Jun 30, 2007	Jun 30, 2008	Jun 30, 2007	Jun 30, 2008
Product revenue	$50,114,528	$47,085,813	$100,020,937	$94,934,021
Service revenue	45,019,357	50,123,189	86,796,039	99,032,108
Total revenue	95,133,885	97,209,002	186,816,97 6	193,966,129
Operations, development	42,211,927	45,321,931	81,282,650	90,145,758
Selling, G & A	20,916,346	21,301,443	40,362,411	42,139,599
Operating expense	63,128,273	66,623,374	121,645,061	132,285,357
Operating income	32,005,612	30,585,628	65,171,915	61,680,772
Other income (loss)	7,225,848	(2,101,951)	12,699,872	3,307,216
Other expense	1,868,298	2,200,159	3,778,915	4,233,170
Pretax income	37,363,162	26,283,518	74,092,872	60,754,818
				< /td>
State income tax	3,112,232	1,979,706	6,194,162	4,611,720
Federal income tax	10,654,696	7,980,117	21,315,488	18,345,161
Income tax	13,766,928	9,959,823	27,509,650	22,956,881
Net income	$23,596,234	$16,323,695	$46,583,222	$37,797,937

Page 4 of 11

Consolidated Cash Flow Statement for the Six Months Ended June 30, 2007 and 2008

	6 months	ended on
	Jun 30, 2007	Jun 30, 2008
Net income	$46,583,222	$37,797,937
Depreciation expense	4,385,144	4,728,087
Amortization expense	0	426,984
Writedown of marketable securities	0	15,016,345
Recovery of a prior writedown	0	(3,483,834)
Gain on sales of marketable securities	(1,560,434)	(7,126,111)
Deferred taxes on unrealized securities losses	1,233,940	2,935,970
Change in accounts receivable	(479,786)	(5,802,891)
Change in accounts payable	3,822,144	3,951,935
Change in taxes payable	(1,917,359)	(3,248,591)
Change in accrued expenses	(4,961,937)	(11,041,152)
Change in customer deposits	(2,873,958)	2,363,589
Change in deferred taxes and tax reserves	(1,009,160)	(9,443,093)
Net cash from operations	43,221,816	27,075,175
Purchases of marketable securities	(30,770,012)	(31,527,010)
Sales of marketable securities	43,317,712	47,086,845
Purchases of fixed assets	(15,198,037)	(8,909,041)
Change in other assets	(3,686,246)	120,000
Net cash (used in) from investing	(6,336,583)	6,770,794
Sales of common stock	8,159,830	7,627,735
Dividen ds paid	(42,341,642)	(44,836,278)
Net cash used in financing	(34,181,812)	(37,208,543)
Net change in cash and equivalents	2,703,421	(3,362,574)
Cash and equivalents at beginning	13,660,733	22,567,940
Cash and equivalents at end	$16,364,154	$19,205,366

Page 5 of 11

Notes To Consolidated Financial Statements

1. The unaudited consolidated financial statements presented herein have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles. These statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2007 included in MEDITECH's Form 10-K filed on January 31, 2008. The unaudited financial statements presented herein have not been audited by our Independent Registered Public Accounting Firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management such financial statements include all normal recurring adjustments necessary to present fairly MEDITECH's financial position, results of operations and cash flow.

2. MEDITECH follows the provisions of Statement of Financial Accounting Standards No. 128 (SFAS 128), Earnings per Share. SFAS 128 requires reporting both basic and diluted earnings per share. MEDITECH has no common share equivalents such as preferred stock, warrants or stock options which would dilute earnings per share. Thus, earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the applicable period.

	3 months	ended on	6 months	ended on
	Jun 30, 2007	Jun 30, 2008	Jun 30, 2007	Jun 30, 2008
Net income	$23,596,234	$16,323,695	$46,583,222	$37,797,937
Average number of shares	35,362,415	35,653,067	35,362,415	35,653,067
Earnings per share	$0.67	$0.46	$1.32	$1.06

The average number of shares outstanding during the periods reflects the issuance of 233,138 shares in February 2007 and 206,155 shares in February 2008 pursuant to the 2004 Stock Purchase Plan.

3. MEDITECH follows the provisions of Statement of Financial Accounting Standards No. 130 (SFAS 130), Reporting Comprehensive Income. SFAS 130 establishes standards for reporting and display of comprehensive income and its components in financial statements. Comprehensive income is the total of net income and all other non-owner changes in equity including items such as net unrealized gains/losses/reclassifications on marketable securities classified as available for sale, foreign currency translation adjustments and minimum pension liability adjustments.

	3 months	ended on	6 months	ended on
	Jun 30, 2007	Jun 30, 2008	Jun 30, 2007	Jun 30, 2008
Net income	$23,596,234	$16,323,695	$46,583,222	$37,797,937
Net unrealized security losses	(3,982,758)	(1,203,614)	(1,850,911)	(4,403,958)
Comprehensive income	$19,613,476	$15,120,081	$44,732,311	$33,393,979

4. MEDITECH follows the provisions of Statement of Financial Accounting Standards No. 115 (SFAS 115), Accounting for Certain Investments in Debt and Equity Securities. SFAS 115 requires companies to classify their investments as trading, available-for-sale or held-to-maturity. MEDITECH's marketable securities consist of common and preferred equities which have been classified as available-for-sale. These are recorded in the financial statements at fair value and any unrealized gains (losses) are reported as a component of deferred taxes and shareholder equity. The fair value of marketable securities was determined based on quoted prices in active markets. In addition MEDITECH holds short and long term U.S. government agency issues which have been classified as held-to-maturity. These are recorded in the financial statements at their cost which approximates their fair value.

Page 6 of 11

SFAS 115 requires that for each individual security classified as available-for-sale, a company shall determine whether a decline in market value below the cost basis is other than temporary. If the decline in market value is judged as such, the cost basis of the individual security shall be reduced to market value and the amount of the write-down shall be reflected in earnings. At June 30, 2008 MEDITECH determined the decline in market value of 6 equity issues we own is other than temporary and reduced their cost basis by $15,016,345 to bring it in line with market value. This write-down was partially offset by a pretax gain of $7,126,111 from the June sale of 2 equity issues.

MEDITECH's resultant marketable securities had a market value of $212,831,468 which included a gross unrealized gain of $5,393,835 and a gross unrealized loss of $10,382,106. The gross unrealized loss was composed of 13 equities with an original cost of $105,326,935 and a market value of $94,944,829. None of these equities had been in loss status for more than 5% of cost for longer than 30 consecutive days. However, the market value of these equities is based upon factors which are not within MEDITECH's control and further deterioration may occur. MEDITECH considered the effect of fluctuating interest rates, current economic and industry conditions, and the issuers' current financial position in order to reach its conclusion that these impairments are temporary at June 30, 2008. MEDITECH continues to evaluate whether the situation warrants further write-downs.

5. During the 2nd quarter 2008 MEDITECH began staff member occupancy of a new facility. MEDITECH spent $6,000,404 for the land, $2,581,312 in architectural and engineering fees, and $33,068,821 in construction costs for this facility.

6. MEDITECH follows the provisions of Financial Accounting Standards Board Interpretation No. 46 (FIN 46), Consolidation of Variable Interest Entities and, as such, accounts for the equity investments in LSS Data Systems Inc. and MEDITECH South Africa in accordance with the cost method. Both companies license MEDITECH's software technology and re-license it to their respective customers. Each serves a market niche which is part of the overall medical market but is outside of the hospital market which MEDITECH serves. Included in these investments is the $2,260,000 balance on a mortgage note from LSS Data Systems Inc. which is fully collateralized by land and buildings owned and occupied as corporate headquarters by the borrower. MEDITECH believes the fair value of these investments which are included in other assets approximates its carrying value of $6,315,702 at June 30, 2008.

Other assets also include both tangible and intangible net assets associated with the 2nd quarter 2007 acquisition of Patient Care Technologies Inc. MEDITECH accounted for this acquisition under the purchase method of accounting in accordance with FASB Statement No. 141, Business Combinations. The values of assets acquired and liabilities assumed, including the identified intangibles, such as developed technology and backlog, are based upon management's estimates of fair value as of the date of acquisition. These identified intangibles are valued at $5,977,801 and are being amortized over their 7 year useful lives. A deferred tax liability was recognized to reflect the tax effect of these identified intangibles as such amounts are not deductible for tax purposes. An acquired deferred tax asset was also recognized to reflect the carryforward of net operating losses expected to be realized.

7. MEDITECH follows the provisions of Financial Accounting Standards Board Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes, which applies to all tax positions related to income taxes subject to SFAS 109, Accounting for Income Taxes. Based on the criteria set forth in FIN 48, MEDITECH's tax reserves amounted to potential tax assessments of $6,410,803 plus interest and penalties of $8,008,180 at December 31, 2007 and $5,916,988 plus interest and penalties of $9,001,995 at June 30, 2008. These reserves relate to the research tax credit, domestic production activities deduction, and state nexus. The years 2006 through 2007 are subject to examination by the IRS, and various years are subject to examination by state tax authorities. Should these tax reserves be reversed in their entirety, the 2008 effective tax rate of 38% would drop to 28%.

Page 7 of 11

8. MEDITECH follows the provisions of Statement of Financial Accounting Standards No. 131 (SFAS 131), Disclosure About Segments of an Enterprise and Related Information. Based on the criteria set forth in SFAS 131, MEDITECH currently operates in one operating segment, medical software and services. MEDITECH derives substantially all of its operating revenue from the sale and support of one group of similar products and services. All of MEDITECH's assets are located within the United States. The following table indicates the source of revenue.

	3 months	ended on	6 months	ended on
Country	Jun 30, 2007	Jun 30, 2008	Jun 30, 2007	Jun 30, 2008
United States	87%	90%	87%	90%
Canada	11%	8%	11%	8%
All others	2%	2%	2%	2%

9. Effective January 1, 2008 MEDITECH adopted the provisions of Statement of Financial Accounting Standards No. 157 (SFAS 157), Fair Value Measurements. SFAS 157 provides for expanded disclosure and guidelines to determine fair value of assets and liabilities. SFAS 157 applies whenever other standards require or permit assets and liabilities to be measured at fair value, but does not expand the use of fair value in any new circumstances. MEDITECH's marketable securities represent assets measured at fair value on a recurring basis.

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations

Results of	3 months	ended on	Percent
Operations	Jun 30, 2007	Jun 30, 2008	Change
Total revenue	$95,133,885	$97,209,002	2.2%
Operating income	32,005,612	30,585,628	(4.4%)
Net income	23,596,234	16,323,695	(30.8%)
Average number of shares	35,362,415	35,653,067	0.8%
Earnings per share	$0.67	$0.46	(31.4%)
Cash dividends per&nb sp;share	$0.60	$0.63	5.0%

Total revenue from both existing and new customers increased by $2.1 million. It was composed of a $3.0 million decrease in product revenue and a $5.1 million increase in service revenue.

Operating expense increased by $3.5 million or 5.5% due primarily to higher staff related costs. The resultant operating income decreased by $1.4 million.

Other income decreased by $9.3 million due primarily to an investment impairment. Other expense increased by $0.3 million due primarily to higher litigation related costs. The resultant pretax income decreased by $11.1 million or 29.7%.

MEDITECH's effective tax rate increased from 36.8% to 37.9% due primarily to the discontinuation of the research tax credit. Net income decreased by $7.3 million due primarily to an investment impairment.

Page 8 of 11

MEDITECH acquired Patient Care Technologies, Inc. in the 2nd quarter of 2007. The following table does not include their operating results for the 1st quarter of 2007.

Results of	6 months	ended on	Percent
Operations	Jun 30, 2007	Jun 30, 2008	Change
Total revenue	$186,816,976	$193,966,129	3.8%
Operating income	65,171,915	61,680,772	(5.4%)
Net income	46,583,222	37,797,937	(18.9%)
Average number of shares	35,362,415	35,653,067	0.8%
Earnings per share	$1.32	$1.06	(19.5%)
Cash dividends per& nbsp;share	$1.20	$1.26	5.0%

Total revenue from both existing and new customers increased by $7.1 million. It was composed of a $5.1 million decrease in product revenue and a $12.2 million increase in service revenue.

Operating expense increased by $10.6 million or 8.7% due primarily to higher staff related costs. The resultant operating income decreased by $3.5 million.

Other income decreased by $9.3 million due primarily to an investment impairment. Other expense increased by $0.5 million due primarily to higher litigation related costs. The resultant pretax income decreased by $13.3 million or 18.0%.

MEDITECH's effective tax rate increased from 37.1% to 37.8% due primarily to the discontinuation of the research tax credit. Net income decreased by $8.8 million due primarily to an investment impairment.

Financial Condition	Dec 31, 2007	Jun 30, 2008
Cash and equivalents	$22,567,940	$19,205,366
Total assets	482,489,043	461,257,171
Total liabilities	69,024,468	51,607,157
Shareholder equity	413,464,575	409,650,014
Outstanding number of shares	35,481,271	35,687,426
Shareholder equity per share	$11.65	$11.48

Accounts payable increased by $4.0 million during the first 6 months primarily because no payroll tax withholding was outstanding at December 31, 2007 while $3.0 million was outstanding at June 30, 2008.

Taxes payable decreased by $3.2 million during the first 6 months due primarily to additional state tax payments in 2008.

Accrued expenses decreased by $11.0 million during the first 6 months primarily as a result of the payment of $27.3 million in bonuses applicable to 2007, offset by the accrual of $16.7 million in bonus expenses applicable to 2008.

At June 30, 2008 MEDITECH's cash, cash equivalents and marketable securities totaled $232.0 million. Marketable securities consisted of preferred equities, common equities and government notes which can easily be converted to cash. For the first 6 months of 2008 cash flow from operations was $27.1 million, cash flow from investing was $6.8 million and cash flow used in financing was $37.2 million. The payment of $44.8 million in dividends to shareholders was the primary use of cash generated by operating activities during the first 6 months.

Page 9 of 11

MEDITECH has no long-term debt. Shareholder equity at June 30, 2008 was $409.7 million. Management anticipates additions to fixed assets will continue, including new facilities and computer systems for product development, sales and marketing, implementation, service and administrative staff. Management believes existing cash, cash equivalents and marketable securities together with funds generated from operations will be sufficient to meet operating and capital expense requirements for the foreseeable future.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

Market risk associated with equity securities is covered in note 4 to Consolidated Financial Statements.

Item 4 - Controls and Procedures

An evaluation was conducted under the supervision and with the participation of MEDITECH's management, including the Chief Executive Officer and Chief Financial Officer, on the effectiveness of MEDITECH's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)14(c) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded MEDITECH's disclosure controls and procedures are, to the best of their knowledge, effective to ensure information requiring disclosure by MEDITECH in reports which it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

There were no changes in MEDITECH's internal control over financial reporting occurring during the fiscal quarter covered by this report which have materially affected or are reasonably likely to materially affect MEDITECH's internal control over financial reporting.

Part II - Other Information

Item 1 - Legal Proceedings

During February 2005 a former employee filed a complaint in the United States District Court for the District of Massachusetts against the Medical Information Technology Profit Sharing Plan and all six of MEDITECH's Directors. The complaint was subsequently amended to add MEDITECH as a defendant. During March 2006 the court dismissed the breach of fiduciary duty claims brought against the individual defendants. The remaining claim is an ERISA benefits claim against the Plan, the Plan's trustee, and MEDITECH. The complaint seeks certification of the case as a class action, a judgment against the defendants, a permanent injunction ordering the Plan to consult an outside appraiser in valuing the Plan's assets, removal of the Plan Trustee, and damages, interest, attorneys' fees and costs. During March 2007 the court denied the plaintiff's motion for the complaint to be certified as a class action. Subsequently the plaintiff requested reconsideration of the decision, which was also denied. The plaintiff then soug ht permission to appeal the decision in the United States Court of Appeals for the First Circuit. In July 2007 this was also denied. Discovery was closed on November 27, 2007. In March 2008 plaintiffs filed an amended motion for class certification, which defendants have opposed. In April 2008 defendants filed a motion for summary judgment, which plaintiffs have opposed. A hearing on the class certification and summary judgment motions took place on June 17, 2008. The result is pending.

Item 1A - Risk Factors

No material changes from risk factors as previously disclosed in the prior Form 10-K.

Page 10 of 11

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

MEDITECH did not repurchase any of its shares of common stock during the 2nd quarter of 2008. However, during the 2nd quarter the Medical Information Technology, Inc. Profit Sharing Trust purchased 4,756 shares of MEDITECH's common stock for a total of $175,972 in individual private transactions. Below is a table showing the purchases of common stock by the Trust during each month of the 2nd quarter of 2008.

2nd quarter	shares	price per
of 2008	purchased	share
April	1,636	$37.00
May	1,455	$37.00
June	1,665	$37.00

Item 3 - Defaults Upon Senior Securities

None.

Item 4 - Submission of Matters to a Vote of Shareholders

None

Item 5 - Other Information

None

Item 6 - Exhibits

Exhibit 3.1: MEDITECH's Articles of Organization, as amended to date, are incorporated by reference to an exhibit to the quarterly report on Form 10-Q for the quarter ended March 31, 2007.

Exhibit 3.2: MEDITECH's By-laws, as amended to date, are incorporated by reference to an exhibit to the annual report on Form 10-K for the year ended December 31, 2001.

Exhibit 31: Rule 13a-14(a) Certifications and Exhibit 32: Section 1350 Certifications are appended to this report.

There were no reports filed on Form 8-K during the quarter ended June 30, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medical Information Technology, Inc.
(Registrant)

July 31, 2008
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

Page 11 of 11

EX-31

Exhibit 31: Rule 13a-14(a) Certifications

CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Barbara A. Manzolillo, Chief Financial Officer and Treasurer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medical Information Technology, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 31, 2008
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

I, A. Neil Pappalardo, Chief Executive Officer and Chairman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medical Information Technology, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

July 31, 2008
(Date)

A. Neil Pappalardo, Chief Executive Officer and Chairman
(Signature)

EX-32

Exhibit 32: Section 1350 Certifications

I, Barbara A. Manzolillo, Chief Financial Officer and Treasurer, certify this quarterly report on Form 10-Q of Medical Information Technology, Inc. (MEDITECH) for the period ended June 30, 2008, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

July 31, 2008
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

I, A. Neil Pappalardo, Chief Executive Officer and Chairman, certify this quarterly report on Form 10-Q of Medical Information Technology, Inc. (MEDITECH) for the period ended June 30, 2008, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

July 31, 2008
(Date)

A. Neil Pappalardo, Chief Executive Officer and Chairman
(Signature)